MENU
LCTX
Stock ticker: ASE
PRICE
CHANGE
CAPITALIZATION

Lineage Cell Therapeutics (LCTX) Ownership - Who owns Lineage Cell Therapeutics?

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases... Show more

A.I.Advisor
Nov 07, 2026

What Is Lineage Cell Therapeutics (LCTX)? Company Overview, Business Model and Market Position

Key Takeaways

  • Lineage Cell Therapeutics is a clinical-stage biotechnology company developing "off-the-shelf" allogeneic cell replacement therapies for serious medical conditions.
  • The company is headquartered in Carlsbad, California, and was originally incorporated in 1990 under the name BioTime, Inc. before rebranding as Lineage in August 2019.
  • Its pipeline is built around its proprietary AlloSCOPE platform and includes programs targeting dry age-related macular degeneration (AMD), spinal cord injuries, hearing loss, and other degenerative diseases.
  • Lineage's lead program, OpRegen, is partnered with Roche and Genentech, giving the company a notable pharmaceutical collaboration for a clinical-stage firm.
  • As a pre-revenue-stage biotechnology company with modest collaboration income, Lineage carries the execution, clinical, and financing risks common to early-stage drug developers.

Introduction

LCTX is the ticker for Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company listed on the NYSE American exchange (and also traded on the Tel Aviv Stock Exchange). The company focuses on regenerative medicine, developing cell replacement therapies intended to restore or support cells that are absent or dysfunctional because of degenerative disease, aging, or traumatic injury. Investors follow Lineage because its pipeline addresses large, underserved markets in ophthalmology and neurology, and because its lead program is backed by one of the world's largest pharmaceutical companies.

Main Profile

Lineage Cell Therapeutics was incorporated in 1990 and was formerly known as BioTime, Inc.; it adopted its current name in August 2019, changing its ticker from BTX to LCTX. The company is headquartered in Carlsbad, California, and employs roughly 70–80 people.

At the center of Lineage's business model is its proprietary cell-based technology platform, AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering). Using directed differentiation protocols applied to established, well-characterized pluripotent cell lines, the company manufactures specialized human cells designed to resemble cells found naturally in the body. Because these therapies are allogeneic — meaning the cells come from a universal donor source rather than from the patient — they can be produced in advance and stored, potentially enabling "off-the-shelf" treatment.

Lineage's pipeline includes several programs across ophthalmology and neurology:

  • OpRegen — a retinal pigment epithelial (RPE) cell replacement therapy in Phase 2a development for geographic atrophy secondary to age-related macular degeneration (AMD), developed under a worldwide collaboration with Roche and Genentech.
  • OPC1 — an oligodendrocyte progenitor cell therapy in Phase 1/2a development for spinal cord injuries.
  • ReSonance (ANP1) — an auditory neuronal progenitor cell therapy in development for auditory neuropathy and other hearing conditions.
  • PNC1 — a photoreceptor neural cell therapy being developed for vision loss.
  • RND1 — a hypoimmune induced pluripotent stem cell (iPSC) line under development through a gene-editing partnership.

As a clinical-stage company, Lineage generates limited revenue, primarily from collaborations and grants rather than product sales. Its business model depends on advancing programs through clinical trials and securing partnerships, milestones, and royalty arrangements. The Roche/Genentech collaboration on OpRegen is the most significant of these partnerships, providing both validation and non-dilutive funding.

Why Investors Follow LCTX

Lineage attracts investor attention primarily because of the scale of the medical problems its therapies target and the strength of its lead collaboration. Age-related macular degeneration and spinal cord injury represent large patient populations with limited treatment options, and a successful cell replacement therapy could address significant unmet medical needs.

The company's allogeneic, "off-the-shelf" approach is also a key differentiator. Unlike autologous cell therapies, which are manufactured from a patient's own cells, allogeneic products can be produced in batches and used across many patients, potentially reducing cost and improving scalability. Lineage's in-house manufacturing capabilities and its track record of producing clinical-grade cell lots are positioned as competitive advantages in a field where manufacturing expertise is a meaningful barrier to entry.

The Roche/Genentech partnership provides external validation of the platform and reduces some of the financial burden of advancing OpRegen, while leaving Lineage with a potential path to milestone payments and royalties. For investors, this combination of a differentiated technology platform, a broad pipeline, and a large pharmaceutical collaboration forms the core of Lineage's long-term investment thesis.

Risks and Important Considerations

Investing in Lineage carries the risks typical of clinical-stage biotechnology. The company's therapies are still in clinical or preclinical development, and there is no guarantee that any program will demonstrate sufficient safety or efficacy to reach regulatory approval or commercialization.

Lineage's financial profile reflects its early stage: it has historically generated modest revenue and recorded net losses, meaning it may need to raise additional capital through equity offerings, partnerships, or debt, which could dilute existing shareholders. The company's fortunes are also closely tied to its collaboration with Roche and Genentech; changes to that partnership, or setbacks in the OpRegen program, could have a material impact.

Additional considerations include intense competition in regenerative medicine and ophthalmology, the regulatory complexity of cell-based therapies, and the clinical and manufacturing risks inherent in developing complex biologics. Investors should understand that these factors make Lineage a higher-risk, longer-horizon investment relative to more established companies.

AI Screener

For investors seeking to identify opportunities across thousands of stocks and ETFs, Tickeron's AI Screener offers an AI-powered discovery platform. The tool helps traders and investors screen for ideas using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. By applying these criteria, users can efficiently narrow a broad universe of securities to those matching their own investment strategies. Explore the AI Screener to streamline your research process.

Conclusion

Lineage Cell Therapeutics occupies a distinctive position in regenerative medicine, combining a proprietary allogeneic cell platform with a pipeline aimed at some of the most challenging diseases in ophthalmology and neurology. Its partnership with Roche and Genentech on OpRegen adds a level of validation and support that is relatively uncommon for a company of its size. At the same time, Lineage remains a clinical-stage enterprise with limited revenue and the substantial risks that accompany drug development. For investors, the company represents a long-horizon opportunity tied to the success of its clinical programs and the broader evolution of cell therapy.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Profile

Industry
N/A
Address
2173 Salk Avenue
Phone
+1 442 287-8990
Employees
77
Web
https://www.lineagecell.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
257.97M
P/E Ratio
-7.29
Total Cash
50.83M
Projected Growth
0.06
Total Debt
2.3M
Revenue
13.08M
Risk (Beta)
1.30
Dividend Yield
N/A
Total Cash/Share
0.20
Total Debt/Equity
N/A
Revenue/Share
0.05 USD as % of share price
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, and neurological conditions

Industry Biotechnology

Industry
N/A
Address
2173 Salk Avenue
Phone
+1 442 287-8990
Employees
77
Web
https://www.lineagecell.com
Who owns Lineage Cell Therapeutics? LCTX symbol Ownership - Tickeron.com